In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly's Chorus Experiment

Executive Summary

With clinical failure rates rising industry-wide, a skunkworks at Lilly, called Chorus, has been trying to boost likely-to-succeed shots on goal by getting compounds to human proof-of-concept far faster and cheaper than the internal organization. Lilly's R&D group is skeptical about the program, even anxious -- one reason Chorus has teamed up with a major venture fund to get more molecules to test. If the program works, will Lilly embrace it - or will its venture partner reap the rewards?

Related Content

Back To School: Big Pharmas Test New Models For Tapping Academia
Inside Lilly Research Laboratories: A Discussion With Jan Lundberg
Flexion Exploits Big Pharma as Discovery Supplier
GSK's Virtual-Proof-of-Concept Unit in Tune with Lilly's Chorus
New Frontiers in Pharma R&D Investment
At PSA, Executives Tout the Benefits of Scale
Cliff Nearing, It's Lilly's Turn to Restructure
Lilly and Merck Lead the Way With Asian FIPNet Strategies
Biopharma: Reviewing 2007 to Forecast 2008
Novartis's Research Experiment


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts